Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

TCT 2021 | TCT 2021: narsoplimab in TA-TMA

Eleni Gavriilaki • 2 Feb 2021
TCT 2021
Eculizumab Narsoplimab

Eleni Gavriilaki, MD, PhD, George Papanicolaou Hospital, Thessaloniki, Greece, outlines studies to be presented at this year’s Transplantation & Cellular Therapy (TCT) meeting evaluating the use of narsoplimab, a MASP-2 inhibitor, in patients with transplant-associated thrombotic microangiopathy (TA-TMA). Dr Gavriilaki highlights two abstracts, the first evaluates the use of narsoplimab in eculizumab-refractory TA-TMA patients, and the second presents the results of an open-label study evaluating the efficacy of narsoplimab in adult patients with TA-TMA. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.

More from Eleni Gavriilaki

0:58
Agents under investigation for the treatment of TA-TMA
Eleni Gavriilaki • 16 Feb 2024
1:03
Cognitive impairment in patients receiving CAR T-cell therapy
Eleni Gavriilaki • 16 Feb 2024
0:52
Long-term complications in patients with hematological malignancies post-SCT
Eleni Gavriilaki • 11 Dec 2023
1:19
The potential of caplacizumab in the treatment of aTTP
Eleni Gavriilaki • 11 Dec 2023
The content of VJHemOnc is intended for healthcare professionals